SCHEMBL25174367

SCHEMBL25174367

O=C(O)c1cc(-c2ccc(Cl)cc2)ccn1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMO O15229 6/20 0.72
MAP4K4 O95819 2/20 0.54
KDM4E B2RXH2 3/20 0.53
ALDH1A1 P00352 3/20 0.53
KDM6B O15054 1/20 0.53
TET3 O43151 1/20 0.53
KDM4A O75164 1/20 0.53
BBOX1 O75936 1/20 0.53
MAPT P10636 1/20 0.53
KDM5A P29375 1/20 0.53
KDM5C P41229 1/20 0.53
ASPH Q12797 1/20 0.53
KDM4D Q6B0I6 1/20 0.53
TET2 Q6N021 1/20 0.53
ALKBH5 Q6P6C2 1/20 0.53
KDM7A Q6ZMT4 1/20 0.53
KDM8 Q8N371 1/20 0.53
TET1 Q8NFU7 1/20 0.53
EGLN2 Q96KS0 1/20 0.53
FTO Q9C0B1 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30800092 0.86 KMO (0.71) KMOKDM4EALDH1A1KDM6BTET3
SCHEMBL7513922 0.86 KMO (0.71) KMOKDM4EALDH1A1KDM6BTET3
SCHEMBL1938975 0.85 KMO (0.67) KMOKDM4EALDH1A1KDM6BTET3
SCHEMBL3355376 0.84 KMO (1.00) KMOKDM4EALDH1A1KDM6BTET3
SCHEMBL24405063 0.84 MAP4K4 (0.53) KMOMAP4K4KDM4EALDH1A1MAPT
SCHEMBL28284992 0.83 KDM4E (0.66) KMOKDM4EALDH1A1KDM6BTET3
SCHEMBL725162 0.82 KMO (0.62) KMOKDM4EALDH1A1KDM6BTET3
SCHEMBL16673126 0.82 KMO (0.62) KMOKDM4EALDH1A1KDM6BTET3
SCHEMBL31301552 0.82 MAP4K4 (0.59) KMOMAP4K4MAPTSMN1; SMN2CNR1
Hydrochloric Acid SCHEMBL1939238 0.82 KMO (0.97) KMOKDM4EALDH1A1KDM6BTET3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4727549-A2 PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS University of Georgia Research Foundation, Inc. (US) 2026-04-22 EP disclosed
US-20260097046-A1 PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS UNIV GEORGIA (US) 2026-04-09 US disclosed
US-20250346575-A1 ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2025-11-13 US disclosed
WO-2024258900-A2 PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2024-12-19 WO disclosed
EP-4431505-A1 ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF Korea Research Institute of Chemical Technology (KR) 2024-09-18 EP disclosed
CN-118234721-A Isoindolinone derivative with glutarimide mother nucleus and application thereof 韩国化学研究院 2024-06-21 CN disclosed
WO-2023085785-A1 ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF 한국화학연구원 2023-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260097046-A1 PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS SUB1, PFN1, HCCS KMO 2781/4885MAP4K4 4387/4885KDM4E 3780/4885
US-20250346575-A1 ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF CRBN, IDH1, IDH2 KMO 2801/4885MAP4K4 3379/4885KDM4E 2129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.